1. Home
  2. OTLY vs NGNE Comparison

OTLY vs NGNE Comparison

Compare OTLY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oatly Group AB

OTLY

Oatly Group AB

HOLD

Current Price

$10.98

Market Cap

337.2M

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.18

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTLY
NGNE
Founded
1994
2003
Country
Sweden
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.2M
327.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
OTLY
NGNE
Price
$10.98
$20.18
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$15.50
$38.50
AVG Volume (30 Days)
70.4K
204.0K
Earning Date
02-11-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$842,996,000.00
N/A
Revenue This Year
$4.69
N/A
Revenue Next Year
$4.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.63
N/A
52 Week Low
$6.00
$6.88
52 Week High
$18.84
$37.27

Technical Indicators

Market Signals
Indicator
OTLY
NGNE
Relative Strength Index (RSI) 33.04 43.48
Support Level $10.97 $19.03
Resistance Level $11.89 $21.32
Average True Range (ATR) 0.54 1.53
MACD 0.01 0.27
Stochastic Oscillator 9.55 27.96

Price Performance

Historical Comparison
OTLY
NGNE

About OTLY Oatly Group AB

Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: